Notice: This company has been marked as potentially delisted and may not be actively trading. Rubius Therapeutics (RUBY) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Fortnite Fans Only Want One Thing from the Rubius SkinSeptember 17, 2024 | msn.comHow to Get the Exclusive Rubius Fortnite DropSeptember 15, 2024 | msn.com‘Expats’ Star Ruby Ruiz to Lead James J. Robinson’s Directorial Debut ‘First Light’ (EXCLUSIVE)April 26, 2024 | yahoo.comVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'March 11, 2024 | bizjournals.comRubius Therapeutics Inc RUBYNovember 5, 2023 | morningstar.comRUBY - Rubius Therapeutics, Inc.August 2, 2023 | uk.finance.yahoo.comNorth American Morning Briefing: Alphabet, -2-July 25, 2023 | morningstar.comRubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On AlternativesMarch 2, 2023 | finance.yahoo.comThinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?February 14, 2023 | marketwatch.comWhy Is Rubius Therapeutics (RUBY) Stock Up 35% Today?February 14, 2023 | msn.comThe Wrap: Ruby's moving to Congress Street, launching new French conceptJanuary 25, 2023 | yahoo.comRuby Wax sparks concern from fans after posting video from hospital bedJanuary 12, 2023 | mirror.co.ukRuby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting bookJanuary 12, 2023 | dailymail.co.ukFormer Rubius CEO jumps to another Flagship spinoutNovember 18, 2022 | finance.yahoo.comRubius Therapeutics lays off most of its staff, explores saleNovember 4, 2022 | finance.yahoo.comRubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic AlternativesNovember 3, 2022 | finance.yahoo.comRubius stock falls over 5% after hours on strategic review, more job cutsNovember 2, 2022 | seekingalpha.comRubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership ChangesNovember 2, 2022 | finance.yahoo.comRubius Therapeutics, Inc. (RUBY)October 28, 2022 | finance.yahoo.comRubius Therapeutics IncOctober 10, 2022 | reuters.comFlagship-backed Vesalius lays off 43%September 19, 2022 | bizjournals.comRubius Therapeutics to Present at Guggenheim Nantucket Therapeutics ConferenceSeptember 19, 2022 | finance.yahoo.comRubius Therapeutics lays off 75% of staff, looks to sell Smithfield facilitySeptember 14, 2022 | bizjournals.comRubius Therapeutics Shifts Its Clinical Focus, Pulls Plug On Two Early-Stage Cancer AssetsSeptember 13, 2022 | finance.yahoo.comRubius Therapeutics scraps platform, lays off 160September 13, 2022 | finance.yahoo.comRubius stock slumps 26% as tumor trials of RTX-240, RTX-224 axed, cuts 75% workforceSeptember 13, 2022 | seekingalpha.comRubius To Discontinue Clinical Trials Of RTX-240, RTX-224 - Quick FactsSeptember 13, 2022 | nasdaq.comRubius Therapeutics Announces Strategic UpdateSeptember 13, 2022 | finance.yahoo.comRubius Therapeutics to Provide Strategic UpdateSeptember 12, 2022 | financialpost.comMorgan Stanley Trims Rubius Therapeutics (NASDAQ:RUBY) Target Price to $1.50Morgan Stanley cut their price target on shares of Rubius Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a report on Friday.September 9, 2022 | marketbeat.comPeering Into Rubius Therapeutics's Recent Short InterestSeptember 7, 2022 | msn.comRubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?August 11, 2022 | finance.yahoo.comRubius Therapeutics: Q2 Earnings InsightsAugust 9, 2022 | msn.comRubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateAugust 9, 2022 | tmcnet.comRubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateAugust 9, 2022 | finance.yahoo.comRubius Therapeutics to Announce Second Quarter 2022 Financial ResultsJuly 26, 2022 | finance.yahoo.comHotSpot Therapeutics Appoints Jose Carmona to Board of DirectorsJuly 19, 2022 | finance.yahoo.comRubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of DirectorsJuly 14, 2022 | finance.yahoo.comRubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual MeetingJune 22, 2022 | finance.yahoo.comRubius Therapeutics Inc - Stock NewsJune 3, 2022 | morningstar.comRubius Therapeutics to Present at the Jefferies Global Healthcare ConferenceJune 1, 2022 | finance.yahoo.com-$0.52 Earnings Per Share Expected for Rubius Therapeutics, Inc. (NASDAQ:RUBY) This QuarterEquities research analysts predict that Rubius Therapeutics, Inc. (NASDAQ:RUBY - Get Rating) will report earnings of ($0.52) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Rubius Therapeutics' earnings, with estimates rangiMay 28, 2022 | marketbeat.comRubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual MeetingMay 26, 2022 | finance.yahoo.comRubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of DirectorsMay 24, 2022 | finance.yahoo.comBinance Coin Now Buys You the Greatest Amount of Rubius Therapeutics in the Past YearMay 23, 2022 | nasdaq.comEquities Analysts Offer Predictions for Rubius Therapeutics, Inc.'s Q3 2022 Earnings (NASDAQ:RUBY)Rubius Therapeutics, Inc. (NASDAQ:RUBY - Get Rating) - Research analysts at SVB Leerink lifted their Q3 2022 EPS estimates for shares of Rubius Therapeutics in a report released on Tuesday, May 10th. SVB Leerink analyst J. Chang now expects that the company will post earnings of ($0.49) per shareMay 13, 2022 | marketbeat.comRubius price target lowered at H.C. Wainwright on trial update for cellular therapyMay 11, 2022 | seekingalpha.comRubius Therapeutics (NASDAQ:RUBY) Given New $8.00 Price Target at HC WainwrightHC Wainwright cut their price target on shares of Rubius Therapeutics from $15.00 to $8.00 in a report on Wednesday.May 11, 2022 | marketbeat.comWhat 6 Analyst Ratings Have To Say About Rubius TherapeuticsMay 10, 2022 | markets.businessinsider.comRubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 10, 2022 | finance.yahoo.com Get Rubius Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter. Email Address What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come. Click here now to watch the full briefing and discover the steps to take today. RUBY Media Mentions By Week RUBY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RUBY News Sentiment▼0.000.48▲Average Medical News Sentiment RUBY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RUBY Articles This Week▼00▲RUBY Articles Average Week Get Rubius Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cyclo Therapeutics News Finch Therapeutics Group News Cognition Therapeutics News Inhibikase Therapeutics News IN8bio News AIM ImmunoTech News NKGen Biotech News Turnstone Biologics News Senti Biosciences News Evaxion Biotech A/S News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RUBY) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rubius Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rubius Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
